C. Naler, S. Schlueter, J. Fessler, A. Rosenthal
General Genomics, Inc.,
United States
Keywords: artificial intelligence, machine learning, traumatic brain injury, TBI, synthetic data, predictive analytics, diffusion MRI, DTI, DWI, convolutional neural networks, cMesh, explainable AI, data governance, healthcare innovation, privacy compliance, sports medicine, military readiness, pediatric healthcare, industrial safety, emergency room triage
Summary:
General Genomics, Inc. (GGI), a Service-Disabled Veteran-Owned Small Business, has developed SYN46™, an innovative AI/ML-driven framework designed to revolutionize the assessment and prevention of Traumatic Brain Injury (TBI). The platform is built upon GGI’s proprietary platform patent, “Synthetic Data Framework and Predictive Analytics for Health Risk Assessment,” and leverages cutting-edge AI/ML methodologies and advanced diffusion MRI (dMRI) modalities, including Diffusion Tensor Imaging (DTI) and Diffusion-Weighted Imaging (DWI). SYN46™ addresses key challenges in TBI diagnostics by generating synthetic, privacy-compliant datasets that simulate individual health trajectories, enabling accurate and reproducible models while maintaining data privacy. The SYN46™ platform incorporates a standards-based data ingestion pipeline that integrates advanced tools such as dbt™, Apache Griffin™, and Great Expectations™. These ensure automated quality control, monitoring, and robust data governance, allowing transparent, auditable data management while safeguarding privacy. To address variability across datasets, SYN46™ utilizes novel transformational embeddings to normalize heterogeneous dMRI formats, creating consistency and enabling scalability. The synthetic datasets generated by SYN46™ are highly representative and mitigate the risks associated with privacy concerns and regulatory constraints, empowering scalable and unconstrained research in TBI diagnostics and other health applications. At the core of SYN46™ lies cMesh, a robust ensemble Convolutional Neural Network (CNN) platform. This architecture applies advanced AI/ML techniques, including bootstrap aggregation, multi-head configurations, dropout layers, and random transfer learning, ensuring model robustness and diagnostic accuracy across diverse datasets. Augmented by forward/reverse generative diffusion processes, cMesh ensures reliable predictions even under variable conditions. Explainable AI (XAI) is seamlessly integrated, providing actionable insights by quantifying the impact of individual biomarkers and delivering correlative assessments of TBI susceptibility and severity. SYN46™ has demonstrated transformative applications across various industries. In sports medicine, it enables the creation of personalized risk profiles for athletes, empowering teams to implement targeted preventive strategies, enhancing safety, and reducing liability. For military operational readiness, the platform supports pre-deployment screenings to identify personnel at higher risk of blast-related injuries, ensuring effective allocation of protective measures and improving mission success. In industrial workforce safety, longitudinal health monitoring identifies cumulative trauma risks, reducing employer liability and enhancing worker safety. Further applications include pediatric healthcare, where SYN46™ supports early diagnosis of developmental risks associated with head injuries, enabling timely interventions and improving long-term health outcomes. In emergency room triage, the platform enhances decision-making by prioritizing critical care resources for patients with higher risks of long-term complications, improving care delivery and reducing costs. Additionally, SYN46™ addresses geriatric healthcare challenges by monitoring cumulative brain trauma in aging populations, supporting proactive care strategies to improve quality of life. The SYN46™ platform is rigorously validated, market-ready, and designed for seamless integration into existing workflows. Its scalability ensures adaptability across industries, offering significant improvements in cost efficiency, resource allocation, and patient outcomes. By leveraging synthetic data, patented predictive analytics, and cutting-edge AI/ML methodologies, GGI is redefining TBI risk assessment and prevention. SYN46™ represents a paradigm shift in healthcare, empowering stakeholders to transition from reactive to proactive strategies while maintaining the highest standards of data privacy and compliance.